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The eﬀects of several vanadates (ie, orthovanadate, pervanadate, and two stable peroxovanadium compounds) on basal and insulin-
stimulated 2-DG transport in insulin target and nontarget cell lines are reported, herein. In nontarget cells, exposure to vanadates
(5×10−6 to 10−4 mol/L)resultedin2-DGtransportstimulatoryresponsessimilartothoseobservedin2-DGtransportpostexposure
to 667nmol/L insulin alone, or insulin in combination with vanadates. In 3T3-L1 adipocytes and L6 myotubes, exposure to a
vanadate compound or 67nmol/L insulin, stimulated 2-DG transport dramatically. Again, this eﬀect on stimulated transport was
similar to 2-DG transport post-treatment with the eﬀective vanadates in combination with insulin. While pervanadate or stable
peroxovanadates stimulated 2-DG transport at 10−5 to 10−6 mol/L, orthovanadate up to 10−4 mol/L was not eﬀective in stimulating
2-DGtransportinanyofthecelllinestested.Thedataindicatethatthevariousperoxovanadatesareclearlysuperiorinsulinmimetics
while a more limited insulin mimesis is observed with orthovanadate over a wide variety of cell types.
INTRODUCTION
Vanadiumisanessentialtraceelementforhigheranimals
[1, 2], whose speciﬁc physiological role has not been eluci-
dated. Vanadate, a phosphate analogue, has been shown to
be an insulin mimetic for a number of in vivo and in vitro
insulin target tissue responses [3, 4, 5, 6, 7, 8]. Apparently,
its ability to inhibit tyrosine phosphatases [9, 10, 11] results
in increased protein phosphorylation leading to insulin-like
eﬀects [12, 13]. Early studies employing vanadate demon-
strated the insulin-like eﬀects which translated into amelio-
ration of blood glucose levels in streptozotocin-treated di-
abetic rats [7, 14, 15]. This has led to a dramatic increase
in studies on vanadium salts as potential treatments for dia-
betes. A number of additional studies using vanadium com-
pounds led to the development of a class of compounds
calledperoxovanadates.EarlydevelopmentsusingH2O2 plus
vanadate resulted in insulin mimetics of short term stability
[16]. These compounds were considerably more active than
vanadate. This was followed by the synthesis of stable perox-
ovanadium compounds which were potent phosphotyrosine
phosphatase inhibitors and powerful insulin mimetics [17].
In this study, we have evaluated the eﬀects of diﬀerent
vanadates (eg, orthovanadate, peroxovanadate, and two sta-
bleperoxovanadiumcompounds),atvariousconcentrations,
(ie, 10−4 to 10−8 mol/L) on basal and insulin-stimulated glu-
cose transport. Further, these studies were performed on a
number of cell cultures including connective tissue derived
human ﬁbroblasts, L6 myoblasts, L6 myotubes, 3T3-L1 ﬁ-
broblasts, and 3T3-L1 adipocytes, to further characterize the
insulin mimesis of the stable peroxovanadates in these cell
cultures.
MATERIALS AND METHODS
Cellculture
Human Fibroblasts. The human ﬁbroblast cell strains were
grown in 1X penicillin/streptomycin antibiotic solution
in modiﬁed Eagle’s medium (MEM) supplemented with
1mmol/L pyruvate and 10% (vol/vol) fetal bovine serum
(FBS).
T h ec e l l sw e r eg r o w ni na na t m o s p h e r eo f5 %C O 2/95%
air and were harvested from appropriate culture vessels af-
ter incubation for 5minutes with 0.02% (wt/vol) EDTA and
1–2minutes with 0.06% (wt/vol) trypsin (Difco Laborato-
ries,Mich,USA).Inallexperiments,thecellstrainswereem-
ployed at passages never exceeding 20 passages.
L6 myoblasts. Myoblasts were grown in Dulbeccos minimum
essential medium (DMEM) containing 10% (vol/vol) FBS.
At approximately 75% conﬂuence, before any myotube dif-
ferentiation was observed, myoblast studies were performed.
For diﬀerentiation studies, the 10% FBS-DMEM was re-
moved and replaced by an equal volume of fusion medium
(α-MEM containing 2% FBS (vol/vol)) [18]. All experiments
were done 4–5days later when more than 85% of the cells
were diﬀerentiated as assessed visually through morphology
changes (ie, myotube formation). Both 10% FBS-DMEM
and 2% FBS α-MEM were supplemented with a 100X peni-
cillin/streptomycin antibiotic solution. L6 cells were subcul-
tured every 3days at about 75% conﬂuence using a split ra-
tio of 1:3. Cells were detached as described above for human
ﬁbroblasts. L6 cells were not used at greater than 14 passages.
3T3-L1 ﬁbroblasts (pre-adipocytes). C e l l sw e r ec u l t u r e dr o u -
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plated and grown to conﬂuence prior to induction of
adipocyte diﬀerentiation. In transport studies, 3T3-L1 ﬁ-
broblasts were used at conﬂuence before induction. In-
duction of adipocyte diﬀerentiation employed the method
of Frost and Lane [19]. At the time of the experiment,
greater than 85% of the cells expressed the adipocyte phe-
notype. This was conﬁrmed visually by observing consid-
erable accumulation of lipid droplets, and by demonstrat-
ing the expression of increased insulin binding and the
GLUT4 insulin responsive transporter—that is by Western
analysis.
Essentially, the activity of the various vanadates was elu-
cidated in insulin target and nontarget cell cultures to de-
termine if these cell types responded similarly. Comparative
results would indicate if similar pathways were operative in
both cell types.
2-DGtransportprocedure
For human ﬁbroblasts, details of the experimental pro-
t o c o lc a nb ef o u n di n[ 20]. Brieﬂy, cells were plated at
104 cells/cm2 on plastic Petri dishes (35mm diameter, Fal-
con) and grown to conﬂuence (usually 6–7days). The cell
monolayers were rinsed once in serum-free MEM, contain-
ing 1µmol/L dexamethasone [21] for human ﬁbroblasts or
serum-free DMEM for other cell types (containing 1mg/ml
bovine serum albumin (BSA)) (0% MEM; and 0% DMEM,
resp) and incubated 24hours before exposure to experi-
mental conditions. Glucose transport was assessed by mea-
suring the uptake of 2-(3H)-deoxy-D-glucose (2-DG) in
PBS (pH 7.4) containing 1mmol/L 2-DG (speciﬁc activity
5mCi/mmol) at 37◦C. Zero-time adsorption controls were
subtracted. At the end of a speciﬁed time interval, the ra-
dioactive medium was removed and the monolayers were
rinsed 4 times with 4◦C PBS containing 5µmol/L cytocha-
lasin B. Then the monolayers were dissolved in 1N NaOH,
and aliquots were taken for liquid scintillation counting and
protein determination [22].
For L6 cells, cells were grown to the appropriate stage
of diﬀerentiation and serum deprived for 18hours in 0%
DMEM. The only other diﬀerence from the preceding pro-
tocol was that 3H 2-DG was employed at a concentration
of 0.05mmol/L (speciﬁc activity 0.023µCi/µmol). All other
conditions were as above.
For 3T3-L1 ﬁbroblasts, whether we measured 2-DG
transport in ﬁbroblasts or adipocytes, the conditions were as
described above for L6 cells except that the serum depriva-
tion time which was only 2hours for the 3T3-L1 adipocytes.
For all cell types, 2-DG uptake was linear and rate-
limiting under the conditions stated in [20, 23, 24, 25].
Cellfractionationandmembraneisolation
3T3-L1 adipocytes from 100mm diameter plastic Petri
plates (Falcon) were treated as described and plasma mem-
branes isolated [25]. In short, after homogenization with a
Dounce homogenizer, a 1000 xg spin to remove unbroken
cellsandnucleiwasperformed.Thiswasfollo wedbya27000
xg spin yielding a crude plasma membrane pellet. A 3-4 fold
increase in ouabain sensitive ATPase activity was observed in
the crude membrane preparation versus the activity seen in
the crude homogenate (data not shown).
Westernanalysisprocedure
The whole cell monolayers or membrane fractions were
suspended in 0.5ml PBS with the proteinase inhibitor
(phenylmethylsulfonyl ﬂuoride) at a ﬁnal concentration of
1mmol/L. Prior to electrophoresis, samples were solubi-
lized in 2% sodium dodecyl sulfate (SDS) (Pierce Chemi-
cal Co), 10% glycerol, 1mmol/L EDTA, 0.002% bromphe-
nol blue, 100mmol/L tris-HCl (pH 6.8). Electrophoresis
was performed as described previously in [24, 25, 26].
Proteins were blotted onto nitrocellulose paper (0.2µm,
Schleicher and Schull, Ontario, Canada) that was blocked
with 1% BSA (1hour at 20◦C). This was followed by
incubation overnight at 4◦C with speciﬁc rabbit poly-
clonal antibody (ie, anti GLUT1, diluted 1:1000 in block-
ing buﬀer). This antibody was induced using a puriﬁed
erythrocyte glucose transporter prepared as described in
[27]. Subsequently, 125-I labeled protein A (ICN), at 1.2 ×
106dpm/10ml in blocking buﬀer containing 0.1% Triton
X-100, was added for 1hour at 20◦C (dpm: disintegrations
per minute). Autoradiography was performed using Ko-
dak XAR ﬁlm (Eastman Kodak, Rochester, NY, USA) ex-
posed at −85◦C overnight. Quantitation was determined
by cutting out the exposed spots and counting in an LKB
gamma counter with an appropriate matching nonlabelled
portion of the blot counted and subtracted for background
detection.
Preparationofvanadateandpervanadatesolutions
The vanadate was prepared as previously described [5].
Pervanadate was prepared by mixing 10−3 mol/L orthovana-
datewithH2O2,for15min ut esat22 ◦C.Thiswasfollowedby
the addition of catalase, 200µg/ml, to remove residual H2O2.
This procedure resulted in an oxidized form of vanadate,
which remained stable for 2hours [28]. Stable peroxovana-
dium compounds [bpV (phen) and bpV (pic)] were synthe-
sized as previously described in [17]. These compounds have
been designated pVA and pVI, respectively.
Insulinbinding
The insulin binding procedure was as described previ-
ously [21]. Brieﬂy, the cell monolayers were washed twice
with 22◦C Hanks HEPES buﬀer containing 0.2% BSA, pH
7.4. Then the monolayers were incubated with 1ng 125I-
insulin alone (total binding) or in the presence of 40µgo f
nonlabeled insulin (nonspeciﬁc binding). After 2hours at
22◦C,themonolayerswererinsedfourtimeswithcoldHanks
HEPES buﬀer containing 0.2% BSA, solubilized with 1N
NaOH and counted in a LKB gamma counter.
Materials
2-(3H)-DG, 125I-protein A, and 125I-NaI were purchased
from ICN Radiochemical Division (Calif, USA). 2-DG was
purchased from Calbiochem (Calif); BSA from Nutritional24 Ralph J. Germinarioa et al 2:1 (2002)
Biochemicals (Ill, USA) and sodium orthovanadate and
phenylmethylsulfonylﬂuoride from Sigma (Mo, USA).
Statistics
Thelevel of signiﬁcancechosen forany statistical analysis
employed herein was 5%.
RESULTS
Effectofvariousvanadateson2-DGtransport
inhumanﬁbroblasts
In Figure 1a, short term exposure (ie, 60minutes) of hu-
man ﬁbroblasts (HF) to increasing concentrations of sodium
orthovanadate resulted in increased 2-DG transport that ap-
peared to peak at 10−5 mol/L. While the data indicated that
10−5 mol/L orthovanadate was a maximally eﬀective concen-
tration, statistical analysis showed that no signiﬁcant diﬀer-
ences existed between the various groups analyzed (1-way
ANOVA; F = 2.983, P>. 05, n = 4, triplicate plates in
each experiment). Signiﬁcant stimulation of 2-DG transport
by 667nmol/L insulin was observed (control, 6.6 ± 0.7v s
insulin, 12 ± 2nmol 2-DG/mg protein/5minutes; P<. 5,
1-way ANOVA) while no signiﬁcant diﬀerence (P>. 05)
was observed +10−5 mol/L orthovanadate. In another series
of experiments, the eﬀects of pervanadate (prepared as de-
scribed in Materials and Methods) [17]o nH Fw e r ei n v e s t i -
gated over a range of concentrations (Figure 1b). The data in
Figure 1b demonstrated signiﬁcant increases in 2-DG trans-
port at both 10−5 mol/L (a>60% average increase over con-
trol) and 10−4 mol/L concentrations (1-way ANOVA, F =
13.1, P<. 05, n = 3, triplicate plates in each experiment
at various concentrations). While insulin (667nmol/L) or
10−5 mol/L pervanadate both signiﬁcantly stimulated 2-DG
transport, no diﬀerences were observed between 10−5 mol/L
pervanadate, or insulin alone or versus both factors in com-
bination (667nmol/L insulin vs 10−5 mol/L pervanadate vs
667nmol/L insulin +10−5 mol/L pervanadate; 21.4 ± 0.5v s
23.7 ± 0.5v s2 4 .1 ± 0.2nmol 2-DG/mg protein/5min; 1-
way ANOVA, P>. 05). Also, stable peroxovanadates [17]
were evaluated over a similar range of concentrations. Signif-
icant stimulation of 2-DG transport was seen at 10−5 mol/L
and 10−4 mol/L pVA (Figure 1c)( 1 - w a yA N O V A ,F = 157.9,
P<. 01, n = 3, triplicate plates in each experiment at
all concentrations). The optimal concentration for pVA was
10−5 mol/L, expressing an average increase ∼400% increase
over control (Figure 1c). For pVI, signiﬁcant increases were
seen from 10−6 to 10−4 mol/L (maximal at 10−5 mol/L) con-
centrations, which yielded increases of ∼300% over con-
trol values (Figure 1d). Additionally, the stimulation in 2-
D Gt r a n s p o r ts e e na t1 0 −6 mol/L pVI was not observed with
any other vanadate compound in HF. In all experiments,
60minutes exposure time were employed as no change in
stimulated 2-DG transport was observed for exposure times
up to 120minutes (data not shown). For both pVA and pVI,
insulin(667nmol/L)versuseitherstableperoxovanadatever-
sus a combination of either with insulin was not signiﬁcantly
diﬀerent (P>. 05; 1-way ANOVA, data not shown).
Effectofvariousvanadateson2-DGtransport
in3T3-L1cells
We next investigated the eﬀect of diﬀerent concentra-
tions of the stable peroxovanadate, pVA on 2-DG trans-
port in 3T3-L1 ﬁbroblasts. The data in Figure 2a demon-
strate that pVA can increase 2-DG transport in these
cells at a concentration of 5 × 10−6 mol/L or greater. The
average stimulation ratio of pVA treated/control trans-
port was between 1.4 and 1.5 fold. This ratio agreed
favorably with the insulin/control transport ratio (1.58
fold). The 2-DG transport in control versus insulin-treated
(ie, 667nmol/L insulin) 3T3-L1 ﬁbroblasts was 0.77nmol
2-DG/mg protein/5min versus 1.2nmol 2-DG/mg pro-
tein/5min, respectively (P<. 05, n = 9, 1-way ANOVA).
The combination of insulin +10−5 mol/L pVA resulted in
similar 2-DG transport values as seen with either treatment
alone (eg, insulin vs insulin +10−5 mol/L pVA 2-DG trans-
port: 1.3 ± 0.5v s1 .5 ± 0.3nmol/mg protein/5min; 1-way
ANOVA). The peak eﬀect of pVA was seen at 5 × 10−6 mol/L
(P<. 05, 1-way ANOVA). In a diﬀerent series of experi-
ments (Figure 2b), employing pVI in 3T3-L1 ﬁbroblasts, 2-
DG transport was increased at 10−5 mol/L and 10−4 mol/L
pVI. The average increase seen in 2-DG transport induced
by pVI was 125% to 143%, respectively (P<. 05, n = 7,
1-way ANOVA). Again, no diﬀerences were seen in the in-
sulin (67nmol/L) versus insulin + pVI (10−5 mol/L) groups;
P>. 05 (data not shown).
Our next series of experiments ascertained the eﬀects
of pVA and pVI on 2-DG transport in 3T3-L1 adipocytes.
3T3 cells were induced as described in [19]a n do v e rap e -
riod of 10days, we observed increases in the cellular con-
tent of GLUT1 (∼3f o l d )a n dG L U T 4( ∼10 fold) (data
not shown). Further, speciﬁc insulin binding was also in-
creased over the period of induction (eg, 12 ± 4.3fmol
125I-insulin/mg p vs 3.5 ± 1.2fmol 125I-insulin/mg protein,
in the 3T3-L1 adipocyte vs the 3T3-L1 ﬁbroblast, resp)
(P<. 05, n = 6, 2-tailed test). In concert with these
changes,insulinresponsivenessincreasedasevidencedbythe
maximally eﬀective insulin concentration for 2-DG trans-
port stimulation in 3T3-L1 adipocytes being ∼67nmol/L
versus 667nmol/L as seen in 3T3-L1 ﬁbroblasts (data not
shown).Additionally,acomparisonofspeciﬁcinsulinstimu-
lation of sugar transport at 67nmol/L for 3T3-L1 adipocytes
and 667nmol/L for 3T3-L1 ﬁbroblasts was signiﬁcantly dif-
ferent (ie, a 400%–600% increase for the adipocytes at
67nmol/L insulin vs a 130% increase for the ﬁbroblasts
at 667nmol/L insulin); (P<. 05, n = 6, 2-tailed test)
(data not shown). Having established the nature of changes
in sugar transport and the sugar transporters in the 3T3
cells (as also demonstrated by a number of other laborato-
ries), we examined the eﬀect of stable peroxovanadates on
2-DG transport. The data in Figure 3a depicts the eﬀect of
diﬀerent concentrations of pVA on 2-DG transport in 3T3-
L1adipocytesafter10daysofinductionoftheadipocytephe-
notype. ItisapparentthatthemaximumeﬀectofpVAisseen
at 10−5 mol/L. The increase in 2-DG transport over control
is, on average, nearly 4-fold at 10−5 mol/L and 10−4 mol/L2:1 (2002) Sugar Transport Modulation by Vanadate 25
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(a) Eﬀect of VO4 on 2-DG transport in human ﬁbroblasts.
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(b) Eﬀect of increasing concentrations of pervanadate on 2DG
transport in human ﬁbroblasts.
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(c) Eﬀect of pVA on 2-DG transport in human ﬁbroblasts.
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(d) Eﬀect of pVI on 2-DG transport in human ﬁbroblasts.
Figure 1. Eﬀect of diﬀerent vanadate compounds at several concentrations on basal and insulin-stimulated 2-DG transport in human ﬁbroblasts. Panel
(a) sodium orthovanadate; no signiﬁcant diﬀerences were seen, P>. 05, 1-way ANOVA, F = 2.983, n = 4 (triplicate plates in all experiments). Panel (b)
pervanadate; P<. 05, 1-way ANOVA, F = 13.1, n = 3 (triplicate plate in all experiments). Panel (c) pVA; ∗P<. 05, 1-way ANOVA, F = 157.9, n = 3( t r i p l i c a t e
plates in all experiments). Panel (d) pVI; ∗P<. 05, 1-way ANOVA, F = 38.2, n = 3 (triplicate plates in all experiments). All data ±SE. The exposure time for
all the vanadate compounds employed was 60minutes. See Materials and Methods for additional experimental details.
pVA. In the same series of experiments, the average insulin
(ie,67nmol/L),orinsulin+10−5 mol/LpVAinducedincrease
in 2-DG transport, was ∼4-fold (data not shown). In another
series of experiments, we employed pVI (Figure 3b) and the
signiﬁcantly eﬀective concentrations of pVI were found to
be 10−5 mol/L (∼5-fold increase) and 10−4 mol/L (∼4-fold in-
crease). Insulin at 67nmol/L elicited an average 4.4-fold in-
crease in 2-DG transport. Next, we sought to demonstrate
the eﬀects of pVA on the translocation of glucose trans-
porters to the cell plasma membrane. In Figure 4,i tc a nb e
seen that exposure to 67nmol/L insulin results in a signif-
icant translocation of the GLUT1 and GLUT4 transporters
into a crude plasma membrane preparation. In the same ex-
periments,inaparallelseriesofplates,the3T3-L1adipocytes
were exposed to 10−5 mol/L pVA and the GLUT1 and GLUT4
content of plasma membranes were determined. Clearly, the
pVA resulted in a signiﬁcant translocation of these trans-
porters in a pattern nearly identical to that observed with
insulin (P<. 05, n = 3; 1-way ANOVA).
Effectofvariousvanadateson2-DGtransport
inL6myoblastsandL6myotubes
The eﬀect of orthovanadate pVA or pVI (10−7 to
10−4 mol/L) on L6 myoblasts was not signiﬁcantly diﬀerent26 Ralph J. Germinarioa et al 2:1 (2002)
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(a) Eﬀect of increasing concentrations of pVA on 2-DG transport in
3T3-L1 ﬁbroblasts.
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(b) Eﬀect of increasing concentrations of pVI on 2-DG transport in
3T3-L1 ﬁbroblasts.
Figure 2. Eﬀect of diﬀerent vanadate compounds at several concentrations
onbasalandinsulin-stimulated2-DGtransportin3T3-L1ﬁbroblasts.Panel
(a) pVA; ∗P<. 05, 1-way ANOVA, F = 8.95, n = 9 (triplicate plates in all
experiments). Panel (b) pVI; ∗P<. 05, 1-way ANOVA, F = 4.99, n = 7
(triplicateplatesinallexperiments).Alldata±SE.pVAorpVIexposuretime
was for 60minutes. See Materials and Methods for additional experimental
details.
from control 2-DG transport (Figure 5)( P>. 05, n = 8,
1-way ANOVA). The myoblasts did respond to 10−5 and
10−4 mol/L pVA (Figure 5) exhibiting a modest increase (ie,
118%–127%, resp) (P<. 05, n = 6, 1-way ANOVA). Addi-
tionally, pVI exposure resulted in increased 2-DG transport
at a concentration of 10−4 mol/L pVI (154%) (P<. 05, n = 6,
1-way ANOVA) (Figure 5). The average insulin-stimulated
(ie, 667nmol/L Insulin) 2-DG transport was 121% ± 9%.
Further, we investigated the eﬀects of these vanadates on
L6 myotubes which exhibited greater than 80% myotube
formation and increased expression of GLUT4 ([25], data
not shown). Again as observed with L6 myoblasts, there
was no signiﬁcant 2-DG transport increases in response to
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(a) Eﬀect of pVA on 2-DG transport in 3T3 adipocytes.
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(b) Eﬀect of pVI on 2-DG transport in 3T3 adipocytes.
Figure 3. Eﬀect of diﬀerent vanadate compounds at several concentrations
onbasalandinsulin-stimulated2-DGtransportin3T3-L1adipocytes.Panel
(a) pVA; ∗P<. 05, 1-way ANOVA, F = 23.3, n = 3 (triplicate plates in all
experiments). Panel (b) pVI; ∗P<. 05, 1-way ANOVA, F = 7.7, n = 3 (tripli-
cate plates in all experiments). All data ±SE. pVA or pVI exposure time was
60minutes. See Materials and Methods for additional experimental details.
orthovanadate (10−810−4 mol/L) (Figure 6)( P<. 05, n = 3,
1-wayANOVA).Further,themyotubesexhibitedincreasesin
2-DG transport only at a concentration of 10−4 mol/L pVA
or pVI (Figure 6)( P<. 05, n = 3, 1-way ANOVA). The ob-
servedincreaseswere153%forpVA,and166%forpVI,these
compared favorably with the increase seen in 67nmol/L in-
sulin (eg, 160%, data not shown). Combinations of any of
the vanadates tested with 67nmol/L insulin did not result in
any change in 2-DG transport as seen with either treatment
(data not shown).
DISCUSSION
We have done an extensive study in a number of cell
lines characterizing the eﬀects of a variety of vanadates on2:1 (2002) Sugar Transport Modulation by Vanadate 27
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Figure 4. Eﬀect of insulin and pVA on GLUT1 and GLUT4 transporter
translocation in 3T3-L1 adipocytes. The GLUT1 and 4 transporters content
are expressed in crude plasma membrane preparations in control, insulin-
treated (ie, 67nmol/L I) and pVA treated (ie, 10−5 mol/L pVA) membranes.
GLUT1: ∗P<. 05;1-wayANOVA,F = 6.8,GLUT4: ∗P<. 05,1-wayANOVA,
F = 7.7, n = 3. All data ±SE.
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Figure 5. Eﬀect of diﬀerent vanadate compounds on 2-DG transport in L6
myoblasts. Sodium orthovanadate ( --- ), no signiﬁcant diﬀerences were
seen. P>. 05, 1-way ANOVA, F = 1.33, n = 8 (triplicate plates in all exper-
iments). pVA (—), ∗P<. 05, 1-way ANOVA, F = 6.43, n = 6( t r i p l i c a t e
plates in all experiments). pVI (—), ∗P<. 05, 1-way ANOVA, F = 13.0,
n = 6 (triplicate plates in all experiments). All data ±SE. The exposure time
for all vanadate compounds was 60minutes. See Materials and Methods for
additional experimental details.
basal and insulin-stimulated 2-DG transport. Clearly, two
patterns of eﬀect have been seen: (1) sodium orthovanadate
was not eﬀective in stimulating basal 2-DG transport in the
cell lines tested and (2) pervanadates were eﬀective in all
cell lines at 10−5 to 10−4 mol/L concentrations. This is sim-
ilar to observations made in [12, 13]. In all of the preceding
data, the increases seen in 2-DG transport at maximally ef-
fective concentrations of diﬀerent vanadates were compara-
ble to insulin-stimulated 2-DG transport, alone or in combi-
nation with a respective vanadate.
The L6 and 3T3-L1 cells were induced to diﬀerenti-
ate into their respective insulin target (ie, the myotube and
adipocyte). Dramatic increases were seen in GLUT1 and
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Figure 6. Eﬀect of diﬀerent vanadate compounds on 2-DG transport in L6
myotubes. Sodium orthovanadate ( --- ): no signiﬁcant diﬀerences were
seen, P>. 05, 1-way ANOVA, F = 0.84, n = 3 (triplicate plates in all exper-
iments). pVA (—): ∗P<. 05, 1-way ANOVA, F = 7.3, n = 3( t r i p l i c a t e
plates in all experiments). pVI (—): ∗P<. 05, 1-way ANOVA, F = 19.8,
n = 3 (triplicate plates in all experiments). All data ±SE. The exposure time
for all vanadate compounds employed was 60minutes. See Materials and
Methods for additional experimental details.
GLUT4 transporter content during 3T3-L1 adipocyte induc-
tion [29, 30, 31]. Additionally, increased sensitivity to in-
sulin was observed in 3T3-L1 adipocytes with insulin (ie,
67nmol/L) to control transport ratios of 4-fold when com-
pared to the average 1.3 to 1.5-fold increases seen with
667nmol/L insulin in 3T3-L1 ﬁbroblasts. Also, we observed
an increased content of GLUT1 and GLUT4 in the crude
plasma membrane fraction (ie, transporter translocation)
of 3T3-L1 adipocytes post exposure to insulin (67nmol/L)
or pVA (10−5 mol/L) (Figure 4). Further, our laboratory
[25] and others [6, 18] have shown that GLUT1, 3, and 4
transporters in L6 myotubes are translocated to the plasma
membrane in response to insulin. The responses seen post-
exposure to pVA or pVI are at least 10-fold less eﬀective
in myotubes than adipocytes. Additionally, the myotubes
do not respond to concentrations of orthovanadate up to
10−4 mol/L. We have not employed concentrations above
10−4 mol/L orthovanadate as considerable toxicity to the
cells has been reported [15, 32, 33, 34, 35]a n dw a so b -
served (data not shown). What is intriguing is that the in-
sulin/control2-DGtransportratiosobserved,weresimilarto
the insulin/control 2-DG transport ratios no matter which
vanadate was employed. It is interesting that similar con-
centrations of diﬀerent vanadate compounds are all maxi-
mally eﬃcacious on 2-DG transport within an order of mag-
nitude (eg, 10−5 to 10−4 mol/L). In other studies employing
rat adipocytes, investigators have seen marginal eﬀects of or-
thovanadate at 10−3 mol/L on insulin receptor β chain ty-
rosine kinase activity [28]. This concentration exhibited a
greater response at similar concentrations with pervanadate
(ie, more than 20-fold increase in insulin receptor β chain
tyrosine kinase activity). In human ﬁbroblasts, pervanadate
exposure leads to a nearly 2-fold increase in basal 2-DG28 Ralph J. Germinarioa et al 2:1 (2002)
transportataconcentrationof10−5 mol/L(insulinreceptorβ
chain tyrosine kinase activity in rat adipocytes at 10−5 mol/L
pervanadate resulted in more than 5-fold increases in en-
zyme activity). In another study, the peak pervanadate eﬀect
on lipogenesis in rat adipocytes was observed at 10−5 mol/L
[16]. In the same study, the peak eﬀect of this vanadate
on protein synthesis was seen at 5 × 10−8 mol/L pervana-
date, while for insulin this peak occurred at 5 × 10−7 mol/L;
and for orthovanadate, the peak stimulation was seen at
5 × 10−5 mol/L [16]. This indicated that the diﬀerent bio-
logical responses will be aﬀected by diﬀerent vanadate com-
pounds at diﬀerent concentrations. In the initial studies em-
ploying stable peroxovanadium compounds [17], maximal
eﬀects of pVA and pVI on lipogenesis in rat adipocytes were
found at 10−6 mol/L and 10−4 mol/L, respectively. The pre-
ceding results are in general agreement with our ﬁndings
on the concentration eﬀects of diﬀerent vanadates on 2-DG
transport in a number of cell lines. The eﬀects on protein
synthesis exhibit greater sensitivity to pervanadate than we
have seen with human ﬁbroblasts. This is not surprising as
this response requires a longer exposure period to observe an
eﬀect. With diﬀerent vanadates, there may be multiple sec-
ondary eﬀects occurring that are beyond our current state of
knowledge.
Our results on 2-DG transport with the L6 myotubes in-
dicated that the peak concentration found for the eﬀect of
pervanadate on 2-DG transport was 10−5 mol/L. This is sim-
ilar to our results for pervanadate seen in human ﬁbroblasts,
and for pVA in L6 myoblasts. Other investigators have shown
an eﬀect of orthovanadate on 2-DG transport but the con-
centration employed at peak eﬀect was 10−2 mol/L [36]. As
our studies, did not exhibit an eﬀect of orthovanadate, em-
ployed no concentration more than 10−4 mol/L orthovana-
date, we may have seen an eﬀect at higher concentrations of
orthovanadate. We do feel that the use of 10−2 mol/L ortho-
vanadateisunacceptableprimarilyregardingsecondarynon-
speciﬁc events due to reasons cited earlier in this text.
The studies reported herein are the most extensive ex-
amination of the eﬀects of various vanadate compounds and
diﬀerent cell types reported to date. Our data show consid-
erable agreement with vanadate eﬀects on lipogenesis, in-
sulin receptor tyrosine kinase, and 2-DG transport regard-
ing the peak eﬀective concentrations and comparisons with
insulin and vanadate treated transport ratios in a variety
of cultured cells, rat adipocytes, and skeletal muscle cells
[5, 6, 16, 17, 18, 36]. Additionally, higher concentrations of
pVA and pVI were expected to show eﬀects on 2-DG trans-
port in 3T3-L1 adipocytes and L6 myotubes. A similar phe-
nomenon was observed by others [5, 37, 38, 39] using ortho-
vanadate and pervanadate to stimulate the biologic eﬀects of
insulin in adipocytes and skeletal muscle.
The eﬀects of a wide spectrum of diﬀerent vanadates on
2-DG transport in multiple cell lines exhibited similar
responses in transport increases, whether the 2-DG trans-
port was increased by 1-fold or 4-fold. Also, this was true
for insulin-treated cells and for insulin plus pervanadate
or peroxovanadate-treated cells but not for orthovanadate
exposed cells. The suggestion is that the mechanism(s)
involved are similar. As to the mechanism(s) involved, it
is generally agreed that the diﬀerent vanadates act via pro-
tein tyrosine phosphatase inhibition [17, 38] and not solely
by the insulin receptor [13]. Additionally, some investiga-
tors have proposed that orthovanadate and pervanadate act
in subtly diﬀerent ways: the former as a competitive in-
hibitor of protein tyrosine phosphatases and the latter as
a completely irreversible oxidizer of the catalytic cysteine
residues of protein tyrosine phosphatase 1B [39]. This mech-
anism cannot exclude eﬀects on other tyrosine kinases such
as the nonreceptor tyrosine kinases (eg, CytPTK) [40]. Ad-
ditionally, membraneous nonreceptor protein tyrosine ki-
nases are activated by vanadates [41]. The preceding how-
ever, may have some bearing on the results obtained herein.
Sodium orthovanadate has demonstrated no eﬀective abil-
ity to stimulate sugar transport at 10−4 mol/L or lower con-
centrations. Thus, its insulin mimetic ability is consider-
ably limited when looking at sugar transport stimulation.
This is readily diﬀerentiated from the insulin mimetic ef-
fects seen with the pervanadates, which are more eﬀective
stimulators of sugar transport (at least 2–3 orders of mag-
nitude when considering 10−2 mol/L as the reported eﬀec-
tive concentration [5, 6, 36] of vanadate on sugar transport).
The pervanadates behave similar to insulin itself. Thus, it
can be argued that the pervanadates are true insulin mimet-
ics via the mechanism cited above [39], unlike orthovana-
date which is considerably less eﬀective in modulating sugar
transport.
Finally, considerable eﬀort has been directed at the po-
tentialofthesecompoundsinthetreatmentfordiabetes.The
data reported herein indicate problems that have been cited
and still must be addressed. These include (1) vanadium tox-
icity,(2)theeﬀectsonnoninsulinresponsivetissues(eg,HF),
(3) the longterm eﬀects on other tissues, and (4) compounds
eﬀective at lower concentrations. The solution to these prob-
lems should lead to the therapeutic use of modiﬁed vana-
date compounds (ie, peroxovanadates) alone or in conjunc-
tion with insulin as an adjunct to diabetes therapy.
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